Mental Process – Talk Bio

Outlook Therapeutics Faces New FDA Setback for First Ophthalmic Avastin Formulation

2 weeks ago talkbio0Tagged AMD, Attitude, Avastin, bevacizumab, Blackfoot language, Clinical Trials, Eight, Glycogen storage disease type II, Lytenava, New-onset refractory status epilepticus, ophthalmic formulation, Rejection, resubmission, United States Food and Drug Administration

Outlook Therapeutics; Avastin; bevacizumab; Lytenava; wet AMD; FDA rejection; NORSE EIGHT; BLA resubmission; ophthalmic formulation; clinical trial

AbbVie Buys Gilgamesh’s Psychedelic Drug Bretisilocin for $1.2B

2 weeks ago talkbio0Tagged AbbVie, Acquisition, bretisilocin, Dosage Forms, Gilgamesh, GM-2505, Hallucinogens, mental health, Neuroscience discipline

AbbVie; Gilgamesh Pharmaceuticals; psychedelic drug; bretisilocin; GM-2505; major depressive disorder; acquisition; mental health; neuroscience; pharmaceutical deal

Novartis antibody ianalumab clinches another Phase 3 win in rare blood disease (ITP)

4 weeks ago talkbio0Tagged Autoimmune, Autoimmune thrombocytopenia, B-cell depletion, ianalumab, Infrequent, Inosine Triphosphate, Novartis, Phase 3, platelet levels, Psychological inhibition, regulatory submissions, Sjögren 's disease, TNFRSF13C protein, human, treatment failure, VAY736

Novartis; ianalumab; VAY736; primary immune thrombocytopenia; ITP; rare disease; Phase 3; time to treatment failure; safe platelet levels; eltrombopag; autoimmune; B-cell depletion; BAFF-R inhibition; Sjögren’s disease; regulatory submissions

CDC Launches ‘Free Mind’ Campaign Targeting Teen Substance Use and Mental Health

1 month ago talkbio0Tagged Adolescence, Alcohol or Other Drugs use, Centers for Disease Control and Prevention (U.S.), Drug Overdose, fentanyl, Free Mind ' Campaign, mental health, Strategy, teen suicide

CDC; Free Mind campaign; youth mental health; substance use; drug overdose; fentanyl; teen suicide; coping strategies

Eisai Adopts Elix Discovery Platform to Accelerate AI-Driven Drug Development

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, DAIIA, Drug Discovery, Eisai, Elix Discovery, federated learning, Initiative, Japan, joint research, pharmaceutical innovation

Eisai; Elix Discovery; AI drug discovery; federated learning; pharmaceutical innovation; joint research; Japan; DAIIA initiative

RFK Jr.’s Revamped ACIP Votes Against Thimerosal in Flu Vaccines, Signaling Shift in Vaccine Policy

3 months ago talkbio0Tagged ACIP, Advisory Committees, anti-vaccine movement, Centers for Disease Control and Prevention (U.S.), Immunization, Influenza virus vaccine, Policy, Practice Experience, Respiratory syncytial virus, RFK Jr., thimerosal, Vaccines

RFK Jr.; ACIP; thimerosal; flu vaccine; vaccine policy; anti-vaccine movement; CDC; RSV shot; Advisory Committee on Immunization Practices

ALTO-203 Misses Depression Endpoint but Shows Positive Biomarker and Cognitive Signals

3 months ago talkbio0Tagged ALTO-203, Attention, Biological Markers, development aspects, drug activity, Electroencephalography, Neuroscience discipline, theta/beta ratio, Wakefulness, William Blair

ALTO-203; Alto Neuroscience; Phase 2 trial; major depressive disorder; EEG biomarkers; theta/beta ratio; attention; wakefulness; William Blair; drug activity; future development

Ousted ACIP Members Criticize RFK Jr.’s ‘Destabilizing’ Changes to U.S. Vaccine Policy

3 months ago talkbio0Tagged ACIP, CDC, Centers for Disease Control and Prevention (U.S.), Committee, Decision, Employment Termination, Policy, public health medicine (field), Recommendation, RFK Jr., Vaccines

ACIP; RFK Jr.; vaccine policy; CDC; committee dismissal; public health; vaccine recommendations; destabilizing decisions

Federal Judge Rules NIH Grant Terminations Illegal, Orders Restoration of Hundreds of Grants

3 months ago talkbio0Tagged Biomedical Research, DEI, federal judge, Gender, health disparity, LGBTQ+, NIH Mouse, public health medicine (field), Racism, Sense of identity (observable entity), terminations, Trump administration

NIH; grant terminations; federal judge; racial discrimination; DEI; gender identity; Trump administration; biomedical research; public health; LGBTQ+; health disparities

GSK Licenses Experimental Shigella Vaccine to Bharat Biotech for Development and Distribution

3 months ago talkbio0Tagged Bharat, biotech, GMMA platform, low, Microbicides, middle-income countries, Resistance (Psychotherapeutic), Shigella Infections, Shigella Vaccines, SmithKline Beecham, vaccine licensing

GSK; Bharat Biotech; Shigella vaccine; altSonflex1-2-3; vaccine licensing; Shigellosis; GMMA platform; antimicrobial resistance; low and middle-income countries